These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38729813)

  • 1. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
    Merali N; Jessel MD; Arbe-Barnes EH; Ruby Lee WY; Gismondi M; Chouari T; O'Brien JW; Patel B; Osei-Bordom D; Rockall TA; Sivakumar S; Annels N; Frampton AE
    HPB (Oxford); 2024 Jul; 26(7):873-894. PubMed ID: 38729813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
    Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring prognostic and immunological characteristics of pancreatic ductal adenocarcinoma through comprehensive genomic analysis of tertiary lymphoid structures and CD8 + T-cells.
    Hu H; Xu Y; Zhang Q; Ai X; Wang T; Li H; Jin C; Ouyang C; Wu Z
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):300. PubMed ID: 38850373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance.
    Zou X; Lin X; Cheng H; Chen Y; Wang R; Ma M; Liu Y; Dai Z; Tasiheng Y; Yan Y; Hou Q; Ding F; Chen H; Yu X; Wang X; Liu C
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
    Balachandran VP; Beatty GL; Dougan SK
    Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
    Kinker GS; Vitiello GAF; Diniz AB; Cabral-Piccin MP; Pereira PHB; Carvalho MLR; Ferreira WAS; Chaves AS; Rondinelli A; Gusmão AF; Defelicibus A; Dos Santos GO; Nunes WA; Claro LCL; Bernardo TM; Nishio RT; Pacheco AM; Laus AC; Arantes LMRB; Fleck JL; de Jesus VHF; de Moricz A; Weinlich R; Coimbra FJF; de Lima VCC; Medina TDS
    Gut; 2023 Oct; 72(10):1927-1941. PubMed ID: 37230755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study.
    Wang YQ; Chen WJ; Zhou W; Dong KQ; Zuo L; Xu D; Chen JX; Chen WJ; Li WY; Liu ZC; Jiang ZY; Tang YF; Qin YX; Wang LH; Pan XW; Cui XG
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy.
    Zou X; Guan C; Gao J; Shi W; Cui Y; Zhong X
    Front Immunol; 2023; 14():1222719. PubMed ID: 37529035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?
    Smith H; Arbe-Barnes E; Shah EA; Sivakumar S
    Front Immunol; 2024; 15():1406250. PubMed ID: 38873607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
    Jin Y; Christenson ES; Zheng L; Li K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):945-958. PubMed ID: 38690749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
    Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
    Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
    Front Immunol; 2021; 12():730746. PubMed ID: 34630409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.